This Saturday's March for Science is trying hard to be a nonpartisan event, but some may not see it that way. » Read More
The new plan to repeal and replace Obamacare is an attempt to bridge the gap between the House Freedom Caucus and moderates. » Read More
There are buying opportunities in biotech and drug stocks despite the backlash from the repeal of Obamacare.
Bank of America predicts Amgen shares could rally 23 percent in the next 12 months.
More than 11.6 million people had signed up by mid-January for Obamacare plans sold on government marketplaces.
Aetna Chief Mark Bertolini also said the insurer is weighing its options after a judge blocked its proposed $37 billion merger with Humana.
"We have to get the prices down," Trump tells drugmakers at the White House.
The No. 3 U.S. health insurer's total revenue rose about 5 percent to $15.73 billion but was below expectations.
Mylan has been under fire since last summer over the rising price of its anti-allergy auto-injector EpiPen device.
Public support for the Affordable Care Act increased by 6 percentage points, as Republicans move toward repealing the law.
The Cleveland Clinic has held a fundraiser at Trump's Mar-A-Lago resort every year since 2011.
Millions of Americans have an abnormal heart rhythm, or cardiac arrhythmia, but monitoring these cases can be cumbersome.
You have until Jan. 31 to buy medical coverage on the state and federal marketplaces.
With hopes for megamergers dashed and Obamacare-fueled growth in question, investors need answers from health insurers.
Republicans want to get rid of Obamacare, but have struggled to craft a replacement for it that would be politically palatable.
Kevin Counihan said several hundred thousand people, many of them young adults, may not sign up on the federal Obamacare exchange now.
More than 8.8 million people have signed up for coverage on the federal Obamacare exchange.
Obamacare's future is in jeopardy. Consumers are turning to digital health start-ups to navigate the complex world of health care.
'At a certain point you can't even price high enough to account for the uncertainty,' a new study says.
Shkreli is accused of looting pharmaceuticals firm Retrophin to pay off hedge fund investors he was suspected of defrauding.
Health regulators warned that third-party financial help for insurance premiums to patients could drive up health costs.
Wells Fargo says Johnson & Johnson will face a significant slowdown in growth in 2017.
Get the best of CNBC in your inbox